News & Updates
Filter by Specialty:
Self-efficacy high among survivors of prostate cancer
Long-term prostate cancer survivors report high levels of self-efficacy, but the contrary is true for subgroups who are facing some challenges, a study presented at EAU 2025 has found.
Self-efficacy high among survivors of prostate cancer
01 May 2025
SC vs IV pembrolizumab: Which route is better for metastatic NSCLC?
In patients with treatment-naive metastatic nonsmall cell lung cancer (NSCLC), subcutaneous (SC) pembrolizumab (pembro) demonstrates comparable efficacy to that of intravenous (IV) pembro as regards overall exposure and trough concentration, reports a study presented at ELCC 2025.
SC vs IV pembrolizumab: Which route is better for metastatic NSCLC?
30 Apr 2025
Neoadjuvant chemo plus durvalumab improves survival in NSCLC
The addition of durvalumab to neoadjuvant chemotherapy with cisplatin and docetaxel results in better survival rates among patients with resectable nonsmall cell lung cancer (NSCLC), according to a study presented at ELCC 2025.
Neoadjuvant chemo plus durvalumab improves survival in NSCLC
30 Apr 2025
Esketamine combined with SSRI or SNRI leads to different outcomes in treatment-resistant depression
Esketamine combined with a serotonin-norepinephrine reuptake inhibitor (SNRI) reduces rates of mortality, hospitalizations, and depressive relapses, while esketamine combined with a selective serotonin reuptake inhibitor (SSRI) decreases the incidence of suicidal attempts, a real-world comparative effectiveness study on treatment-resistant depression (TRD) has shown.